Lymphoma Clinical Trial
Official title:
Feasibility of Combined CT Colonography and PET Imaging for Detection of Colonic Involvement by Mantle Cell Lymphoma
The goal of this clinical research study is to learn if positron emission tomography
(PET)/computed tomography (CT) scanning can be used to detect mantle cell lymphoma in the
colon. Researchers want to learn if PET/CT scanning can produce good-quality images and/or
find the exact locations of lymphoma in the body.
Primary Objective is to determine if combined CT colonography and full body PET scan is
technically feasible and can produce diagnostic scans as well as accurate anatomic
coordination for detection of mantle cell lymphoma involvement of the colon.
Colonoscopy Testing:
A colonoscopy is a routine test where the doctor looks at the inner lining of the colon
using a long, flexible, lighted tube that is inserted through the anus. This is the standard
procedure for detecting mantle cell lymphoma in the colon.
PET/CT Scanning:
Because PET/CT scanning is less invasive than colonoscopy, researchers want to learn more
about whether PET/CT scanning may be able to be used for detecting mantle cell lymphoma in
the colon.
PET/CT scanning is also considered a routine test for checking the status of mantle cell
lymphoma. The scan is called "full body" because the neck, chest, abdomen (stomach area),
and pelvis are included.
In this study, participants will have a full-body PET/CT procedure performed like they
normally would, but the difference will be that gas will be pumped into the colon before the
scan. This is so the colon will be opened up (inflated) so the study doctor will be able to
more easily look for any lesions. The procedure is called gas insufflation. (In standard
PET/CT scanning of the colon, gas insufflation is not used.)
Study Participation:
If you agree to take part in this study, you will begin the PET/CT procedure, as usual. This
means a special substance called fluorodeoxyglucose will be injected by vein, in order to
make the tumor more visible in the scanned image.
About an hour later, the study doctor will prepare your colon for the PET/CT scan by
performing gas insufflation. To do so, a soft plastic tube will be inserted through your
anus. Carbon dioxide gas will be automatically pumped into your colon until the gas is at
the correct pressure.
If the study doctor decides it is necessary (for example, if cramping occurs), you will
receive a glucagon injection under the skin in order to relax the colon. Glucagon is a
medication that helps to relax the colon and decrease cramping. If continued cramping
occurs, the gas will be turned off which results in immediate relief. This is considered
routine for the CT part of the PET/CT. Administering the gas for the CT is similar to the
sensation that will be felt during the colonoscopy when the colon is also insufflated.
After the gas insufflation, the routine PET/CT scan will be performed to check the status of
the disease. You will lie on your stomach for the first part of the PET/CT scan and on your
back for the second part.
After the PET/CT scan, the routine colonoscopy will be performed. You will need to sign a
separate consent form for the colonoscopy, and the procedure will be explained to you in
detail.
Length of Study:
Your participation in this study will be over after the PET/CT scan. Researchers will
compare the results of the PET/CT scan to the results of the colonoscopy.
This is an investigational study. Gas insufflation and glucagon are FDA approved for use
with CT colonography (colonoscopy that uses CT scanning), which is typically used to screen
for colon cancer. PET/CT scanning is FDA approved for use in checking the status of mantle
cell lymphoma. Using PET/CT scanning to detect mantle cell lymphoma in the colon, however,
is investigational. For this purpose, at this time PET/CT scanning is being used in research
only.
Up to 43 patients will take part in this study. All will be enrolled at M. D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |